Royal Bank of Canada Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $123.00
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price reduced by research analysts at Royal Bank of Canada from $126.00 to $123.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank of Canada’s price target indicates a potential upside of 52.85% […]
More Stories
PureTech Health (NASDAQ:PRTC) Stock Price Down 6.3% – Time to Sell?
PureTech Health plc (NASDAQ:PRTC – Get Free Report)’s stock price traded down 6.3% during mid-day trading on Thursday . The...
Intellia Therapeutics Announces Financial and Strategic Updates in Recent 8-K Filing
Intellia Therapeutics, Inc. (NASDAQ:NTLA) recently shared significant updates in its 8-K SEC filing, highlighting key financial and strategic changes. The...
Professional Diversity Network Receives Delisting Notice from Nasdaq
Professional Diversity Network, Inc. (NASDAQ: IPDN) recently disclosed that on January 9, 2025, it received a letter from Nasdaq, indicating...
Fresh Vine Wine Receives Notice of Noncompliance with NYSE American Listing StandardsCharlotte, NC – January 10, 2025 – Fresh Vine Wine, Inc. (“Fresh Vine”) (NYSE American: VINE) has recently been informed that it is not in compliance with Section 70
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
Hemostemix (CVE:HEM) Trading 31% Higher – Still a Buy?
Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 31% during trading on Thursday . The company traded...
Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) Stock Price Down 1% – Here’s What Happened
Shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN – Get Free Report) were down 1% during trading on Thursday ....